SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting Mar 2, 2021
SCYNEXIS to Participate in Maxim Group’s Late Stage Innovations in Women’s Health Virtual Event Feb 25, 2021
SCYNEXIS and Amplity Health Announce Agreement to Support the Anticipated U.S. Commercialization of BrexafemmeTM (Ibrexafungerp) for Vaginal Yeast Infections Feb 23, 2021
SCYNEXIS Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Ibrexafungerp in Greater China Feb 17, 2021
SCYNEXIS Announces Closing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants Dec 22, 2020
SCYNEXIS Announces Pricing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants Dec 17, 2020
SCYNEXIS Announces Advancement of Ibrexafungerp’s Intravenous Formulation to Clinical Stage and Provides Further Updates on its Clinical Studies in Patients with Life-Threatening Fungal Infections Dec 10, 2020
SCYNEXIS Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infections Dec 7, 2020
